Trevi Therapeutics Shares Jump After Complete Data From Chronic Cough Trial

  • Trevi Therapeutics Inc TRVI announced results from the full set of subjects in its Phase 2 CANAL trial of Haduvio for treating chronic cough in idiopathic pulmonary fibrosis (IPF). 
  • Following the statistically significant efficacy results from interim analysis (N=26) conducted in February 2022, the company concluded enrollment early in March 2022.
  • Topline data from the full set of subjects (N=38) in the Phase 2 CANAL trial was statistically significant for the trial's primary endpoint and showed a 52.5% change compared to placebo, with a 75.1% reduction in daytime cough frequency.
  • In a post-hoc analysis, 97% of Haduvio subjects had at least a 30% reduction in 24hr cough frequency compared to 35% of placebo subjects, signifying a clinically meaningful reduction in cough.
  • Based on the Clinical Global Impression of Change rating measuring clinicians' view of change since the start of the trial, 62% of Haduvio subjects improved vs. baseline compared to 19% of placebo subjects.
  • Key secondary endpoints on patient and clinician-reported outcomes were also statistically significant.
  • The company plans to start its subsequent clinical trial in chronic cough patients in the first half of 2023. 
  • Price Action: TRVI shares are up 1.23% at $3.30 on the last check Monday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsPenny StocksHealth CareMoversTrading IdeasGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!